Oncogenes, Cancer, and Hemostasis

Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment

Volumn , Issue , 2007, Pages 1-15

  Boccaccio, Carla ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865112176     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420048001-5     Document Type: Chapter

References (74)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8):789-799.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70.
3. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5(4):311-321.
4. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124(6):1111-1115.
5. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006; 66(4):1883-1890.
6. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194(4260):23-28.
7. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999; 9(12):M57-M60.
8. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6(12):924-935.
9. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002; 2(3):221-225.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917):860-867.
11. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6(5):392-401.
12. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4(11):839-849.
13. Boccaccio C, Medico E. Cancer and blood coagulation. Cell Mol Life Sci 2006; 63(9):1024-1027.
14. Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l’Hotel-Dieu de Paris. Paris: JB Ballière et Fils, 1865:654-712.
15. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta haematol 2001; 106:6-12.
16. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6(6):401-410.
17. Prandoni P, Piccioli A. Thrombosis as a harbinger of cancer. Curr Opin Hematol 2006; 13(5):362-365.
18. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343(25):1846-1850.
19. Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins, 2005:851-873.
20. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006; 35(1-2):103-110.
21. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47:315-331.
22. Smith WL, De Witt DL, Garavito RM. Cyclooxygenases: structural, Cellular, and Molecular Biology. Annu Rev Biochem 2000; 69:145-182.
23. Dahlback B. Blood coagulation. Lancet 2000; 355(9215):1627-1632.
24. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82(2):165-174.
25. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82:259-270.
26. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005; 434(7031):396-400.
27. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65(4):1406-1413.
28. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105(4):1734-1741.
29. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2(4):289-300.
30. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6(8):637-645.
31. Trusolino L, Pugliese L, Comoglio PM. Interactions between scatter factors and their receptors:hints for therapeutic applications. FASEB J 1998; 12:1267-1280.
32. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4(12):915-925.
33. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3(4):347-361.
34. Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau’s syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res 2001; 61(3):795-798.
35. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marrott KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346:74-76.
36. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. NEJM 2000; 342:1792-1801.
37. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-128.
38. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-928.
39. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2003; 276:33964-33968.
40. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2(11):879-890.
41. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61(4):1733-1740.
42. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7(7):505-516.
43. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(suppl 4):S9-S15.
44. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3(1):11-22.
45. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432(7015):307-315.
46. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22(17):3551-3555.
47. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6(3):184-192.
48. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96(8):4240-4245.
49. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30(1):31-44.
50. Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol 2006; 24(3):126-133.
51. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32(1):54-70.
52. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57(23):5391-5398.
53. Dvorak HF. Tumors: wounds that do not heal. NEJM 1986; 315:1650-1659.
54. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275(3):1521-1524.
55. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3(8):1894-1904.
56. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993; 69(5):406-414.
57. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62(23):6966-6972.
58. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrinogen increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105(1):178-185.
59. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996; 93(13):6258-6263.
60. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383(6595):73-75.
61. Ott I, Weigand B, Michl R, et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005; 111(3):349-355.
62. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407(6801):258-264.
63. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32(suppl 1):61-68.
64. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10(5):502-509.
65. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23(2):410-417.
66. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104(9):2746-2751.
67. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22(2-3):205-222.
68. Durand MK, Bodker JS, Christensen A, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91(3):438-449.
69. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383(6599):441-443.
70. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160:781-791.
71. Stefansson S, Lawrence DA. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE 2003; 2003(189):e24.
72. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66(20):9794-9797.
73. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002; 62(1):28-32.
74. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66(6):2923-2927.